Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Glp-1 buddy support This product is amazing
Sustainable weight loss occurs when medication supports behavior change, metabolic improvement, and long-term habits
SURMOUNT-1, 72-week study of adults with obesity using Zepbound (tirzepatide 15mg)
Topline A Chinese pharmaceutical company is seeking approval to market Jiyoutai, an alternative to Ozempic that could be the first biosimilar drug to compete with Novo Nordisks weight-loss and diabetes drugs in China ahead of a potential flood of new obesity medicines in the countryespecially as Novo Nordisks patent is set to expire in 2026
US$ 20.06
US$ 27.40
US$ 28.04
